F Farinati

Summary

Affiliation: University of Padova
Country: Italy

Publications

  1. ncbi request reprint Oxidative DNA damage in circulating leukocytes occurs as an early event in chronic HCV infection
    F Farinati
    Cattedra Malattie Apparato Digerente, Istituto di Medicina Interna, Universita di Padova, Italy
    Free Radic Biol Med 27:1284-91. 1999
  2. ncbi request reprint How should patients with hepatocellular carcinoma be staged? Validation of a new prognostic system
    F Farinati
    Cattedra Malattie Apparato Digerente, Dipartimento di Scienze Chirurgiche e Gastroenterologiche Università di Padova, Italy
    Cancer 89:2266-73. 2000
  3. ncbi request reprint Imbalance between cytoproliferation and apoptosis in hepatitis C virus related chronic liver disease
    F Farinati
    Sezione di Gastroenterologia, Dipartimento di Scienze Chirurgiche e Gastroenterologiche, Universita di Bologna, Italy
    J Viral Hepat 8:34-40. 2001
  4. ncbi request reprint Does the choice of treatment influence survival of patients with small hepatocellular carcinoma in compensated cirrhosis?
    F Farinati
    Cattedra di Gastroenterologia Sezione di Gastroenterologia, Dipartimento di Scienze Chirurgiche e Gastroenterologiche, Policlinico Universitario, Padova, Italy
    Eur J Gastroenterol Hepatol 13:1217-24. 2001
  5. ncbi request reprint DNA oxidative damage in leukocytes correlates with the severity of HCV-related liver disease: validation in an open population study
    R Cardin
    Dipartimento Scienze Chirurgiche e Gastroenterologie, Sezione di Gastroenterologia, Policlinico Universitario, Padova, Italy
    J Hepatol 34:587-92. 2001
  6. ncbi request reprint Hepatitis C virus: from oxygen free radicals to hepatocellular carcinoma
    F Farinati
    Dipartimento di Scienze Chirurgiche e Gastroenterologiche, Sezione di Gastroenterologia, Policlinico Universitario, Universita di Padova, Padova, Italy
    J Viral Hepat 14:821-9. 2007
  7. ncbi request reprint Percutaneous radiofrequency thermal ablation for hepatocellular carcinoma
    A Baldan
    Dipartimento di Scienze Chirurgiche e Gastroenterologiche, Universita di Padova, Padova, Italy
    Aliment Pharmacol Ther 24:1495-501. 2006
  8. doi request reprint Fas / FasL system, IL-1beta expression and apoptosis in chronic HBV and HCV liver disease
    M Bortolami
    Department of Surgical and Gastroenterological Sciences, University of Padua, Padua, Italy
    J Viral Hepat 15:515-22. 2008
  9. doi request reprint Sorafenib in advanced hepatocellular carcinoma
    Josep M Llovet
    Barcelona Clinic Liver Cancer Group, Institut d Investigacions Biomediques August Pi i Sunyer, Centro de Investigaciones en Red de Enfermedades Hepáticas y Digestivas Hospital Clínic Barcelona, Barcelona
    N Engl J Med 359:378-90. 2008
  10. ncbi request reprint Experimental hepatology applied to stem cells
    P Burra
    Department of Surgical and Gastroenterological Sciences, University of Padua, Italy
    Dig Liver Dis 40:54-61. 2008

Detail Information

Publications28

  1. ncbi request reprint Oxidative DNA damage in circulating leukocytes occurs as an early event in chronic HCV infection
    F Farinati
    Cattedra Malattie Apparato Digerente, Istituto di Medicina Interna, Universita di Padova, Italy
    Free Radic Biol Med 27:1284-91. 1999
    ..Serum levels of thiobarbituric acid reactive substances (TBARS) were also assessed as an index of lipid peroxidation...
  2. ncbi request reprint How should patients with hepatocellular carcinoma be staged? Validation of a new prognostic system
    F Farinati
    Cattedra Malattie Apparato Digerente, Dipartimento di Scienze Chirurgiche e Gastroenterologiche Università di Padova, Italy
    Cancer 89:2266-73. 2000
    ....
  3. ncbi request reprint Imbalance between cytoproliferation and apoptosis in hepatitis C virus related chronic liver disease
    F Farinati
    Sezione di Gastroenterologia, Dipartimento di Scienze Chirurgiche e Gastroenterologiche, Universita di Bologna, Italy
    J Viral Hepat 8:34-40. 2001
    ..APO and MIB1 are directly related to the extent of liver damage and, from a biochemical point of view, to tissue iron levels...
  4. ncbi request reprint Does the choice of treatment influence survival of patients with small hepatocellular carcinoma in compensated cirrhosis?
    F Farinati
    Cattedra di Gastroenterologia Sezione di Gastroenterologia, Dipartimento di Scienze Chirurgiche e Gastroenterologiche, Policlinico Universitario, Padova, Italy
    Eur J Gastroenterol Hepatol 13:1217-24. 2001
    ..Untreated patients with small, single hepatocellular carcinoma (HCC) in compensated cirrhosis are characterized by a relatively good prognosis...
  5. ncbi request reprint DNA oxidative damage in leukocytes correlates with the severity of HCV-related liver disease: validation in an open population study
    R Cardin
    Dipartimento Scienze Chirurgiche e Gastroenterologie, Sezione di Gastroenterologia, Policlinico Universitario, Padova, Italy
    J Hepatol 34:587-92. 2001
    ..This genomic damage may contribute to liver carcinogenesis by causing persistent DNA changes...
  6. ncbi request reprint Hepatitis C virus: from oxygen free radicals to hepatocellular carcinoma
    F Farinati
    Dipartimento di Scienze Chirurgiche e Gastroenterologiche, Sezione di Gastroenterologia, Policlinico Universitario, Universita di Padova, Padova, Italy
    J Viral Hepat 14:821-9. 2007
    ....
  7. ncbi request reprint Percutaneous radiofrequency thermal ablation for hepatocellular carcinoma
    A Baldan
    Dipartimento di Scienze Chirurgiche e Gastroenterologiche, Universita di Padova, Padova, Italy
    Aliment Pharmacol Ther 24:1495-501. 2006
    ..Radiofrequency thermal ablation is the first therapeutic option in percutaneous treatment of hepatocellular carcinoma but data on its long-term efficacy and safety are not conclusive...
  8. doi request reprint Fas / FasL system, IL-1beta expression and apoptosis in chronic HBV and HCV liver disease
    M Bortolami
    Department of Surgical and Gastroenterological Sciences, University of Padua, Padua, Italy
    J Viral Hepat 15:515-22. 2008
    ....
  9. doi request reprint Sorafenib in advanced hepatocellular carcinoma
    Josep M Llovet
    Barcelona Clinic Liver Cancer Group, Institut d Investigacions Biomediques August Pi i Sunyer, Centro de Investigaciones en Red de Enfermedades Hepáticas y Digestivas Hospital Clínic Barcelona, Barcelona
    N Engl J Med 359:378-90. 2008
    ..A preliminary study suggested that sorafenib, an oral multikinase inhibitor of the vascular endothelial growth factor receptor, the platelet-derived growth factor receptor, and Raf may be effective in hepatocellular carcinoma...
  10. ncbi request reprint Experimental hepatology applied to stem cells
    P Burra
    Department of Surgical and Gastroenterological Sciences, University of Padua, Italy
    Dig Liver Dis 40:54-61. 2008
    ..The fact that numerous specialties were represented helped the audience to understand the stem cell research area from different standpoints, and what research has achieved so far...
  11. ncbi request reprint Squamous cell carcinoma antigen in human liver carcinogenesis
    M Guido
    Department of Diagnostic Medical Sciences and Special Therapies, Universitè degli Studi di Padova, Italy
    J Clin Pathol 61:445-7. 2008
    ..Squamous cell carcinoma antigen (SCCA) is a serine protease inhibitor that can be overexpressed in hepatocellular carcinoma (HCC) at both molecular and protein level, but no data are available on its expression in pre-malignant stages...
  12. ncbi request reprint Intention-to-treat analysis of liver transplantation in selected, aggressively treated HCC patients exceeding the Milan criteria
    U Cillo
    Unità di Chirurgia Epatobiliare e Trapianto Epatico, Dipartimento di Chirurgia Generale e Trapianti d Organo, Azienda Ospedaliera di Padova, Italy
    Am J Transplant 7:972-81. 2007
    ..None of the 68 transplanted patients had recurrent HCC after a median 16-month follow-up (0-69 months). In conclusion, LT may be effective for selected, aggressively-treated HCC patients exceeding the Milan criteria...
  13. ncbi request reprint Gemcitabine and liposomal doxorubicin in biliary and hepatic carcinoma (HCC) chemotherapy: preliminary results and review of the literature
    D Pastorelli
    O U C Medical Oncology, Busonera Hospital 1 floor, National Oncology Institute of Veneto, IOV IRCCS, Padua, Italy
    Ann Oncol 17:v153-7. 2006
    ..Systemic chemotherapy in hepatocellular carcinoma represents a palliative treatment. Gemcitabine in combination with Liposomal Doxorubicin (LD) may represent an active treatment option...
  14. pmc Complications of radiofrequency thermal ablation in hepatocellular carcinoma: what about "explosive" spread?
    C Angonese
    Gut 55:435-6. 2006
  15. ncbi request reprint Extended lymphadenectomy (D2) in patients with early gastric cancer
    D Nitti
    Department of Oncological and Surgical Sciences, University of Padova, Padova, Italy
    Eur J Surg Oncol 31:875-81. 2005
    ..To investigate the survival benefit of extended lymphadenectomy (D2) in EGC patients in one European Institution...
  16. pmc Microsatellite instability and gastric non-invasive neoplasia in a high risk population in Cesena, Italy
    M Rugge
    Department of Oncology and Surgical Sciences, University of Padova, I 35121 Padova, Italy
    J Clin Pathol 58:805-10. 2005
    ..In this retrospective cross sectional study, microsatellite instability (MSI) was analysed in a consecutive series of NiN and NiN related histological alterations from a northern Italian region at high risk for gastric cancer...
  17. ncbi request reprint Digestive neuroendocrine tumours: diagnosis and treatment in Italy. A survey by the Oncology Study Section of the Italian Society of Gastroenterology (SIGE)
    V D Corleto
    Chair of Gastroenterology, II Faculty of Medicine, La Sapienza University, Rome, Italy
    Dig Liver Dis 33:217-21. 2001
    ..Surgery plays a major role in the treatment of these tumours in all centres. Overall, in only a small number of patients was a multidisciplinary approach applied...
  18. ncbi request reprint Cytokine, infiltrating macrophage and T cell-mediated response to development of primary and secondary human liver cancer
    M Bortolami
    Department of Surgical and Gastroenterological Sciences, University of Padua, Italy
    Dig Liver Dis 34:794-801. 2002
    ....
  19. pmc The long term outcome of gastric non-invasive neoplasia
    M Rugge
    Department of Oncological and Surgical Sciences, III Cattedra di Anatomia Patologica, Università degli Studi di Padova Azienda Ospedale Padova, Italia
    Gut 52:1111-6. 2003
    ..This prospective long term follow up study investigates the clinicopathological behaviour of non-invasive gastric neoplasia (and related lesions), focusing on the cancer risk associated with each different histological phenotype...
  20. doi request reprint HCV histological recurrence and survival following liver transplantation in patients with and without hepatocellular carcinoma
    E De Martin
    Department of Surgical and Gastroenterological Sciences, Gastroenterology, Padova University, Padova, Italy
    Transplant Proc 40:1974-5. 2008
    ..HCV recurrence after LT is universal. This study evaluated HCV recurrence and survival in patients transplanted for HCV and HCC...
  21. pmc Atrophic gastritis: pathology and endoscopy in the reversibility assessment
    M Rugge
    Gut 52:1387-8. 2003
  22. pmc Gastric precancerous lesion follow up based on pathological evidence
    M Cassaro
    J Clin Pathol 57:1007-8. 2004
  23. ncbi request reprint A reappraisal of the Barcelona Clinic Liver Cancer model: natural history of untreated 'intermediate stage' hepatocellular carcinoma
    F Farinati
    J Intern Med 256:529-30; author reply 531. 2004
  24. ncbi request reprint Tumour staging, morphology and p53 overexpression concur in predicting survival in hepatocellular carcinoma
    S Gianni
    Gastroenterology Unit, Department of Surgical and Gastroenterological Sciences, Padua University School of Medicine, 35128 Padova, Italy
    J Intern Med 257:367-73. 2005
    ..The prognosis of hepatocellular carcinoma (HCC) on cirrhosis is hard to predict as it depends on tumour stage, underlying liver disease, type of treatment and, possibly, biological factors of the tumour itself...
  25. ncbi request reprint The Veneto Region's Barrett's Oesophagus Registry: aims, methods, preliminary results
    G Zaninotto
    Department of General Surgery and Organ Transplantation, University of Padova, Padova, Italy
    Dig Liver Dis 39:18-25. 2007
    ..A Barrett's Oeosphagus Registry has been therefore established in the Veneto Region and neighbouring provinces...
  26. pmc Pathology and cost effectiveness of endoscopy surveillance for premalignant gastric lesions
    M Rugge
    Gut 52:453-4. 2003
  27. ncbi request reprint Tamoxifen in the treatment of hepatocellular carcinoma: 5-year results of the CLIP-1 multicentre randomised controlled trial
    F Perrone
    CLIP secretariat, Ufficio Sperimentazioni Cliniche Controllate, Istituto Nazionale Tumori, Via Mariano Semmola, Napoli, 80131, Italy
    Curr Pharm Des 8:1013-9. 2002
    ..control. Here we report an updated analysis of the study results 4.5 years after the closure of enrollment...
  28. pmc Octreotide and hepatocellular carcinoma
    F Farinati
    Br J Cancer 96:1778-9. 2007